Iva Igracki
Director, Medical Affairs Europe, Global Medical Lead, Innovative Dermatology Portfolio Glenmark Pharmaceuticals
Seminars
Tuesday 18th November 2025
Workshop B: Strategic Decision-Making & Closing the Gap in Dermatology
11:25 am
The immunodermatology landscape is rapidly evolving with new targets, modalities, and deeper pathway insights. Success depends not only on selecting the “right” targets and building a future-ready pipeline but also on ensuring that approved therapies reach eligible patients. This integrated session brings together strategic R&D decision-making and real-world implementation challenges to provide a holistic view of innovation and access in dermatology.
Key Objectives
- Prioritize Targets and Pathways: Define criteria for selecting interleukins, immune cells, and mechanisms, leveraging translational insights and early clinical validation
- Design Future-Ready Pipelines: Shape dermatology portfolios strategically—balancing commercial opportunity, patient needs, and long-term differentiation
- Evaluate Innovation & Impact: Apply frameworks to assess clinical and commercial potential, ensuring candidates deliver meaningful innovation and internal buy-in
- Bridge Approval to Access: Address market access, pricing, reimbursement, and adoption barriers; enhance clinician engagement and patient inclusion to close treatment gaps
*Lunch will be served during this workshop at 12pm
Wednesday 19th November 2025
Panel Discussion: Can Topical and Systemic Therapies Each Find Their Place in the Future of Dermatology Drug Development?
4:30 pm
- How should we balance the clinical and commercial drivers behind topical and systemic innovation, especially as realworld prescribing habits continue to favor topicals? How are these approaches viewed from the patient, regulator and investor perspective?
- Which factors, including disease severity, body surface area, and treatment setting, best guide whether a topical, systemic, or combination approach is most appropriate? How can we best utilize both routes to ensure there is a treatment fit for everyone?
- How are both approaches evolving to better meet patient needs, from systemics tackling severe or widespread disease to topicals aiming for convenience, safety, or even disease modification?
- What are the key trade-offs between topical and systemic treatments in terms of patient adherence, cost, quality of life, and long-term disease control and how can trials be designed to reflect this?
